Cannara Biotech Inc. has announced its fiscal second quarter 2024 financial and operating results for the three and six-month periods ended February 29, 2024. Highlights include: Net revenue, increased to $19.7 million in Q2 2024 from $13.0 million in Q2 2023, a 51.0% increase. Gross profit, before fair value adjustments, increased to $7.1 million in Q2 2024 from $4.0 million in Q2 2023, a 77.2% increase. Delivered a twelfth consecutive quarter of positive Adjusted EBITDA 1 of $3.5 million.

Cannara Biotech Inc., a client of our Bristol Investor Relations company, is a vertically integrated producer of premium-grade cannabis and derivative product offerings.

Read the full press release here: Cannara Biotech Reports Q2 2024 Financial Results